Am J Clin Pathol

1. ALJABBAN A, Azevedo RS, Antel K, Arnette A, et al
   Mutational signature analysis of chronic lymphocytic leukemia uncovering genomic patterns and prognostic implications.
   Am J Clin Pathol. 2025 Aug 15:aqaf059. doi: 10.1093.
   

   >> Share

   
   

   
   Am J Hematol

2. DUMINUCO A, Venanzi A, Santi A, Mancini A, et al
   Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy.
   Am J Hematol. 2025 Aug 23. doi: 10.1002/ajh.70043.
   

   >> Share

   
   
3. CHATILA R, Beziat G, Pirovano L, Bouyssie C, et al
   Partial Nuclear Extrusion in Chronic Lymphocytic Leukemia Observed to Be an In Vitro Artefact.
   Am J Hematol. 2025 Aug 22. doi: 10.1002/ajh.70041.
   

   >> Share

   
   
4. OTHMAN T, Baird JH, Wang Y, Pak S, et al
   Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
   Am J Hematol. 2025 Aug 20. doi: 10.1002/ajh.70038.
   

   >> Share

   
   

   
   Ann Hematol

5. YANG Y, Zhang X, Jiang N, Jin Y, et al
   Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
   Ann Hematol. 2025 Aug 26. doi: 10.1007/s00277-025-06535.
   

   >> Share

   
   

   
   Blood

6. CHENG W, Yi X, Wang Z, Li JF, et al
   Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
   Blood. 2025 Aug 19:blood.2024027692. doi: 10.1182/blood.2024027692.
   

   >> Share

   
   
7. ANNESLEY C, Seidel K, Wu Q, Summers C, et al
   Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
   Blood. 2025;146:789-801.
   

   >> Share

   
   

   
   BMC Cancer

8. KONG M, Yang Y, Wu Z, Li Y, et al
   Leveraging diverse liquid-liquid phase separation patterns to predict the prognosis and immunotherapy of pediatric acute myeloid leukemia.
   BMC Cancer. 2025;25:1326.
   

   >> Share

   
   

   
   Bone Marrow Transplant

9. CHEN H, Xu LP, Zhang XH, Wang Y, et al
   Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
   Bone Marrow Transplant. 2025 Aug 18. doi: 10.1038/s41409-025-02698.
   

   >> Share

   
   
10. CHAUVET P, Saade C, Demaret J, Beauvais D, et al
    Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.
    Bone Marrow Transplant. 2025 Aug 21. doi: 10.1038/s41409-025-02700.
    

    >> Share

    
    
11. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699.
    

    >> Share

    
    
12. O'CONNOR TE, Lin C, Roloff GW, Zhang A, et al
    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02693.
    

    >> Share

    
    

    
    Br J Haematol

13. TINAJERO J, Ngo D, Motta M, Agrawal V, et al
    The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.
    Br J Haematol. 2025;207:426-431.
    

    >> Share

    
    
14. BORJA-MONTES OF, Toro-Pedroza A, Epperla N, Andritsos LA, et al
    Hairy cell leukaemia and pregnancy: A systematic review and review of literature.
    Br J Haematol. 2025;207:678-682.
    

    >> Share

    
    

    
    Cancer

15. LIAN J, Zhuang X, Chen Y, Lin Q, et al
    Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2025;131:e70053.
    

    >> Share

    
    
16. CAIROLI R, Del Castello L, Imbergamo S, Pierdomenico E, et al
    Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.
    Cancer. 2025;131:e70055.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

17. SY SKB, Yang Y, Darstein C, Yoon DY, et al
    Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.
    Cancer Chemother Pharmacol. 2025;95:83.
    

    >> Share

    
    

    
    Exp Hematol

18. YOSHIDA S, Onozawa M, Yokoyama S, Matsukawa T, et al
    Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
    Exp Hematol. 2025;149:104819.
    

    >> Share

    
    
19. SANGHA G, Huntly BJP
    Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.
    Exp Hematol. 2025;149:104821.
    

    >> Share

    
    

    
    Gene

20. DHIFLAOUI A, Almawi WY
    Mechanisms and clinical implications of microRNA associations and signaling pathways in B-cell acute lymphoblastic leukemia.
    Gene. 2025 Aug 17:149730. doi: 10.1016/j.gene.2025.149730.
    

    >> Share

    
    

    
    J Clin Oncol

21. PLATZBECKER U, Ades L, Montesinos P, Ammatuna E, et al
    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
    J Clin Oncol. 2025 Aug 18:JCO2500535. doi: 10.1200/JCO-25-00535.
    

    >> Share

    
    
22. ILAND HJ
    APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.
    J Clin Oncol. 2025 Aug 18:JCO2501496. doi: 10.1200/JCO-25-01496.
    

    >> Share

    
    
23. DINARDO CD, Marvin-Peek J, Loghavi S, Takahashi K, et al
    Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
    J Clin Oncol. 2025;43:2692-2699.
    

    >> Share

    
    

    
    J Natl Cancer Inst

24. ZHENG DJ, Hettinger G, Aftandilian C, Bona K, et al
    Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
    J Natl Cancer Inst. 2025 Aug 20:djaf234. doi: 10.1093.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

25. KURTIPEK FB, Damar C, Gokcek E, Gulhan B, et al
    Rare Pancreatitis-Related Complications of L-Asparaginase in Pediatric Acute Lymphoblastic Leukemia: A Case With Pseudocyst and Panniculitis and Literature Review.
    J Pediatr Hematol Oncol. 2025 Aug 25. doi: 10.1097/MPH.0000000000003110.
    

    >> Share

    
    
26. KANG J, Kanukollu S, Bevinetto A, Corless R, et al
    Comparing Tolerability and Toxicity of Calaspargase-Pegol and Pegaspargase in Pediatric Leukemia Patients.
    J Pediatr Hematol Oncol. 2025 Aug 22. doi: 10.1097/MPH.0000000000003098.
    

    >> Share

    
    

    
    Leuk Lymphoma

27. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    

    >> Share

    
    
28. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    

    >> Share

    
    
29. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    

    >> Share

    
    

    
    Leuk Res

30. RAVIPATI S, Bakheet W, Woldie I, Gupta R, et al
    Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.
    Leuk Res. 2025;157:108087.
    

    >> Share

    
    
31. ZHANG TY, Ge AY, Epstein MM, Patel SA, et al
    Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study.
    Leuk Res. 2025;157:108086.
    

    >> Share

    
    
32. FATHI AT, Smith BD, Angiolillo A, Binder G, et al
    Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.
    Leuk Res. 2025;157:107925.
    

    >> Share

    
    
33. KELLAWAY SG
    Targeting growth signals in leukemia: A case of mistaken identity.
    Leuk Res. 2025;157:107935.
    

    >> Share

    
    

    
    Leukemia

34. TELZEROW E, Gorlich D, Sauerland C, Rothenberg-Thurley M, et al
    Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.
    Leukemia. 2025 Aug 22. doi: 10.1038/s41375-025-02735.
    

    >> Share

    
    
35. ZHENG J, Jin L, Chen Y, Duan Y, et al
    Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.
    Leukemia. 2025 Aug 21. doi: 10.1038/s41375-025-02743.
    

    >> Share

    
    
36. FERRAO BLANCO MN, Kazybay B, Belderbos M, Heidenreich O, et al
    Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.
    Leukemia. 2025 Aug 15. doi: 10.1038/s41375-025-02734.
    

    >> Share

    
    
37. AMARAL P, Christie R, Gresham DOF, Lucas EJM, et al
    Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share